CFDE Data Portal | Search MSX2

	Label	Description
	MSX2 Gene (Entity type)	ENSG00000120149 - msh homeobox 2
	MSX2 associations Collection (Entity type)	Associations for MSX2_associations
	MSX2 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE216043 7 V 9 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 8 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 0 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 14 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 7 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

MSX2

ENSG00000120149 - msh homeobox 2

MSX2 associations

Associations for MSX2_associations

MSX2 associations.tsv

A file from IDG as part of the Harmonizome project

GSE216043 7 V 9 CISPLATIN HUMAN DN

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

A Gene Set from LINCS

GSE213588 trametinib NF1 8 v 11 human up

A Gene Set from LINCS

GSE172016 2 V 0 PACLITAXEL HUMAN DN

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 14 v 1 human dn

A Gene Set from LINCS

GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 7 v 3 human up

A Gene Set from LINCS

GSE238213 dopamine 1 v 0 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.